omniture
logo
Search
ABBISKO THERAPEUTICS上海和誉生物
Media Room

Photo News

rss
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

2024-09-19 09:00 4291
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

2023-05-28 21:00 2991
Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting

Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting

2023-04-17 08:30 3298
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial

The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial

2023-03-16 10:00 3340
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

2023-01-30 11:00 3361
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

2022-07-04 13:34 2055